Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses.
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
Melanomas in children and adolescents: Clinicopathologic features and survival outcomes
The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (≥15 mm in thickness)
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity
First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Melanoma pathology reporting and staging
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas